Molecular Studies on the Anti-Tumor Effects of Metal-Based Complexes: Involvement of the Ubiquitin-Proteasome and Apoptotic Pathways Sara M

Total Page:16

File Type:pdf, Size:1020Kb

Molecular Studies on the Anti-Tumor Effects of Metal-Based Complexes: Involvement of the Ubiquitin-Proteasome and Apoptotic Pathways Sara M Wayne State University Wayne State University Dissertations 1-1-2014 Molecular Studies On The Anti-Tumor Effects Of Metal-Based Complexes: Involvement Of The Ubiquitin-Proteasome And Apoptotic Pathways Sara M. Schmitt Wayne State University, Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations Part of the Molecular Biology Commons, and the Oncology Commons Recommended Citation Schmitt, Sara M., "Molecular Studies On The Anti-Tumor Effects Of Metal-Based Complexes: Involvement Of The Ubiquitin- Proteasome And Apoptotic Pathways" (2014). Wayne State University Dissertations. Paper 915. This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. MOLECULAR STUDIES ON THE ANTI-TUMOR EFFECTS OF METAL- BASED COMPLEXES: INVOLVEMENT OF THE UBIQUITIN- PROTEASOME AND APOPTOTIC PATHWAYS by SARA M. SCHMITT DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2014 MAJOR: CANCER BIOLOGY Approved by: Advisor Date ©COPYRIGHT BY SARA M. SCHMITT 2014 All Rights Reserved DEDICATION For my family. For my parents: Mom and Dad, thank you for your never-ending love and support. You have always inspired me to succeed and I would not be who or where I am today without you. I am lucky to have had parents that always let me try anything (within reason) at least once, and for letting me decide when I had taken on too much. Thank you for always being there to cheer me on or pick me up when I was down, even if it meant dropping everything else to be there. Thank you for always encouraging me and pushing me to succeed, especially in those times when I was ready to give up. Thank you for always believing in me and knowing that I could, and would, succeed if I put my mind to it. Words cannot express how grateful I am for all of the sacrifices you have made for me throughout my life. To my sisters: Christa and Libbie, thank you for remaining the unique women that you are and for reminding me to have a little fun sometimes. Thank you for always cheering me on and for the little notes of encouragement when you couldn’t be there in person. Finally, thank you for forcing me to be a better version of myself so that you had someone to look up to and be proud of. For my husband: Curtis, you have been with me throughout this whole process and I never would have gotten through this without your love and support. I am so grateful for your patience and encouragement through all of my ups and downs. Thank you for always letting me follow my path and for pushing me to try new things. Your generally stress-free attitude towards life has grounded me and for that I am extremely grateful. Thank you for being you and for allowing me to be me. ii ACKNOWLEDGEMENTS This dissertation would not have been possible without the mentorship of Dr. Q. Ping Dou, who accepted me into his lab and gave me the guidance necessary to complete such a work. Thank you for giving me the many opportunities to participate in such a variety of projects as well as for trusting me to independently write research articles, reviews, editorials and book chapters. I know that these opportunities, as well as the collaborations that I have participated in, have expanded my skills and will be useful in the future. Thank you to my committee members, Dr. Julie Boerner, Dr. Sreenivasa Chinni, Dr. Arun Rishi and Dr. Jeremy Kodanko, for all of your guidance in all matters of my graduate studies. Your questions and advice have been invaluable throughout this process. Thank you also to the Graduate Program in Cancer Biology, especially individually Dr. Larry Matherly, Dr. George Brush and Dr. Malathy Shekhar, for everything you’ve done for me. I know that my time in this program will afford me success in the future. Thank you to Dajena Tomco and Dr. Claudio Verani, as well as Dr. Jai Prakash and Dr. Jeremy Kodanko, from the Department of Chemistry at Wayne State University and Dr. Chiara Nardon and Dr. Delores Fregona from the University of Padova for synthesizing the many compounds for me to work with. Our collaborations have been extremely productive and I am glad that I was given the opportunity to work with all of you. Thank you to Dr. Christine Neslund- Dudas and Dr. Bharati Mitra for formulating the ALAD project and for allowing me to contribute to the early discussions and final product. I would be remiss if I did not thank all of the members of the Dou lab, both past and present. Special thanks to Dr. Min Shen and Dr. Daniela (Buac) Ventro for always discussing data and iii offering suggestions, as well as to Dr. Di Chen and Cindy Cui for training and helping me with experiments when needed. Thank you also to Jian Zuo for your collaboration on the XIAP project. Finally, thank you to the friends I’ve made here, without whom this experience would have lacked any sanity. Elizabeth Tovar, thank you for always being there for me no matter what, I am so lucky and grateful to have a wonderful friend like you. Thank you again to Daniela, for being not only a great colleague, but also a friend; your advice was always appreciated. iv TABLE OF CONTENTS Dedication ii Acknowledgements iii List of Tables vii List of Figures viii Chapter 1. Introduction 1 Ubiquitin-Proteasome Pathway 1 Apoptosis 8 Proteasome Inhibitors 10 δ-Aminolevulinic Acid Dehydratase 24 Metals in Cancer Development 28 Metal-based Complexes as Proteasome Inhibitors 29 Proteasome Inhibition via Metal Chelation 35 Chapter 2. Materials and Methods 39 Chapter 3. The Heme Synthesis Enzyme δ-Aminolevulinic Acid Dehydratase (ALAD) as an Endogenous Inhibitor of the Proteasome: Involvement of ALAD-20S Proteasome Complexes in Ubiquitination and Acetylation of Proteasomal α2 Subunits 48 Results 49 Discussion 61 Chapter 4. Metal Complexes Targeting the Proteasomal Core 65 4.1 Effects of Tethered Ligands and of Metal Oxidation State on the Interactions of Cobalt Complexes with the 26S Proteasome Results 76 Discussion 84 v 4.2 Gold(III)-Dithiocarbamato Peptidomimetics in the Forefront of the Targeted Anticancer Therapy: Preclinical Studies against Human Breast Neoplasia Results 85 Discussion 101 4.3 Inhibition of the 26S Proteasome as a Possible Mechanism for Toxicity of Heavy Metal Species Results 103 Discussion 111 4.4 Differential Effects of Ga(III)- and Zn(II)-Tethered Ligands on Proteasome Activity and Apoptosis in Cultured Prostate Cancer Cells Results 113 Discussion 121 4.5 Nitroxoline Inhibits the Tumor Proteasome and Suppresses Tumor Growth Results 122 Discussion 132 Chapter 5. Metal Chelators Destabilize the E3 Ligase X-linked Inhibitor of Apoptosis (XIAP): Novel Polypyridyl Chelators Deplete Cellular Zinc and Destabilize the X-linked Inhibitor of Apoptosis Protein (XIAP) Prior to Induction of Apoptosis in Human Prostate and Breast Cancer Cells 133 Results 134 Discussion 147 References 150 Abstract 189 Publications 191 Autobiographical Statement 194 vi LIST OF TABLES Table 1. Structures of Compounds Targeting Upstream Factors. 23 Table 2. AuD6 and 8 inhibit proteasome activity under cell-free conditions. 90 vii LIST OF FIGURES Figure 1. Structure of the 26S Proteasome. 4 Figure 2. Ubiquitin-Proteasome Pathway. 7 Figure 3. The UPP and Apoptosis. 9 Figure 4. Structures of Peptide Aldehyde Proteasome Inhibitors. 11 Figure 5. Structures of Naturally Occurring Proteasome Inhibitors. 13 Figure 6. Structure of Bortezomib. 15 Figure 7. Structures of Next-Generation Proteasome Inhibitors. 20 Figure 8. Heme Biosythesis and ALAD Structure. 26 Figure 9. Structures of Gallium Complexes. 32 Figure 10. Structures of Gold Complexes. 34 Figure 11. Structures of Metal Chelators Used as Proteasome Inhibitors. 38 Figure 12. ALAD binds the 20S proteasome in place of the 19S regulatory cap and is associated with ubiquitinated forms of α2 in cultured prostate cancer cells. 51 Figure 13. ALAD binds the 20S proteasome and is associated with ubiquitinated forms of α2 in human erythrocytes. 52 Figure 14. ALAD is both an inhibitor and a target of the proteasome. 54 Figure 15. SAHA treatment enhances the ALAD-proteasome interaction, associated with acetylation of ubiquitinated α2 subunits. 56 Figure 16. SAHA-treatment promotes nuclear localization of ALAD and modified α2. 58 Figure 17. Purified ALAD promotes ubiquitination of proteasomal α2 under cell free conditions. 60 Figure 18. Proposed Mechanism of ALAD-Proteasome Binding. 64 Figure 19. Structures of Cobalt Compounds. 67 Figure 20. Structures of New Gold(III) Complexes. 69 viii Figure 21. Structures of Heavy Metal Complexes. 71 Figure 22. Structures of Tethered Ga(III) and Zn(II) Complexes. 73 Figure 23. Structures of Nitroxoline and Clioquinol. 75 Figure 24. Complex 3, the Co(III) species, inhibits PC-3 cell proliferation. 77 Figure 25. Complex 3 inhibits purified 20S proteasome activity. 79 Figure 26. Complex 3 inhibits cellular proteasome activity. 81 Figure 27. Complex 3 induces apoptosis in PC-3 cells. 83 Figure 28. Aud6 and AuD8 are potent inhibitors of cellular proliferation. 86 Figure 29. Trolox enhances the anti-proliferative ability of AuD6. 88 Figure 30. AuD6 and 8 inhibit intact cellular proteasome in MDA-MB-231 cells. 92 Figure 31. AuD6 and 8 inhibit intact cellular proteasome and induce apoptosis in MDA-MB-231 cells. 94 Figure 32. AuD6 and 8 induce apoptosis in MDA-MB-231 cells. 96 Figure 33. AuD8 inhibits the proteasome and tumor growth in vivo. 98 Figure 34.
Recommended publications
  • Toward Personalized Treatment in Waldenström Macroglobulinemia
    | INDOLENT LYMPHOMA:HOW UNDERSTANDING DISEASE BIOLOGY IS INFLUENCING CLINICAL DECISION-MAKING | Toward personalized treatment in Waldenstrom¨ macroglobulinemia Jorge J. Castillo and Steven P. Treon Bing Center for Waldenstrom¨ Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Waldenstrom¨ macroglobulinemia (WM) is a rare lymphoma with 1000 to 1500 new patients diagnosed per year in the United States. Patients with WM can experience prolonged survival times, which seem to have increased in the last decade, but relapse is inevitable. The identification of recurrent mutations in the MYD88 and CXCR4 genes has opened avenues of research to better understand and treat patients with WM. These developments are giving way to per- sonalized treatment approaches for these patients, focusing on increasing depth and duration of response alongside lower toxicity rates. In the present document, we review the diagnostic differential, the clinical manifestations, and the pathological and genomic features of patients with WM. We also discuss the safety and efficacy data of alkylating agents, proteasome inhibitors, monoclonal antibodies, and Bruton tyrosine kinase inhibitors in patients with WM. Finally, we propose a genomically driven algorithm for the treatment of WM. The future of therapies for WM appears bright and hopeful, but we should be mindful of the cost-effectiveness and long-term toxicity of novel agents. Diagnostic considerations Learning Objectives The differential diagnosis of WM includes immunoglobulin M (IgM) • To understand recent advances on the biology of Waldenstrom¨ monoclonal gammopathy of undetermined significance; other macroglobulinemia IgM-secreting lymphomas, especially marginal zone lymphoma (MZL); • To review available and investigational agents for the treat- and the rare IgM multiple myeloma (MM).
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • WO 2017/173206 Al 5 October 2017 (05.10.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2017/173206 Al 5 October 2017 (05.10.2017) P O P C T (51) International Patent Classification: CA 94121 (US). HUBBARD, Robert; 7684 Marker Road, A61K 31/52 (2006.01) C07D 473/02 (2006.01) San Diego, CA 92087 (US). MIKOLON, David; 6140 A61K 31/505 (2006.01) C07D 473/26 (2006.01) Calle Empinada, San Diego, CA 92120 (US). RAYMON, A61K 31/519 (2006.01) C07D 473/32 (2006.01) Heather; 3520 Vista de la Orilla, San Diego, CA 921 17 (US). SHI, Tao; 4650 Tarantella Lane, San Diego, CA (21) International Application Number: 92130 (US). TRAN, Tam, M.; 8953 Libra Drive, San PCT/US20 17/025252 Diego, CA 92126 (US). TSUJI, Toshiya; 4171 Donald (22) International Filing Date: Court, San Diego, CA 921 17 (US). WONG, Lilly, L.; 871 3 1 March 2017 (3 1.03.2017) Viva Court, Solana Beach, CA 92075 (US). XU, Suichan; 9650 Deer Trail Place, San Diego, CA 92127 (US). ZHU, (25) Filing Language: English Dan; 4432 Calle Mar De Armonia, San Diego, CA 92130 (26) Publication Language: English (US). (30) Priority Data: (74) Agents: BRUNER, Michael, J. et al; Jones Day, 250 Ve- 62/3 17,412 1 April 2016 (01.04.2016) US sey Street, New York, NY 10281-1047 (US). (71) Applicant: SIGNAL PHARMACEUTICALS, LLC (81) Designated States (unless otherwise indicated, for every [US/US]; 10300 Campus Point Drive, Suite 100, San kind of national protection available): AE, AG, AL, AM, Diego, CA 92121 (US).
    [Show full text]
  • Proteasome Inhibitors for the Treatment of Multiple Myeloma
    cancers Review Proteasome Inhibitors for the Treatment of Multiple Myeloma Shigeki Ito Hematology & Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba-cho 028-3695, Japan; [email protected]; Tel.: +81-19-613-7111 Received: 27 December 2019; Accepted: 19 January 2020; Published: 22 January 2020 Abstract: Use of proteasome inhibitors (PIs) has been the therapeutic backbone of myeloma treatment over the past decade. Many PIs are being developed and evaluated in the preclinical and clinical setting. The first-in-class PI, bortezomib, was approved by the US food and drug administration in 2003. Carfilzomib is a next-generation PI, which selectively and irreversibly inhibits proteasome enzymatic activities in a dose-dependent manner. Ixazomib was the first oral PI to be developed and has a robust efficacy and favorable safety profile in patients with multiple myeloma. These PIs, together with other agents, including alkylators, immunomodulatory drugs, and monoclonal antibodies, have been incorporated into several regimens. This review summarizes the biological effects and the results of clinical trials investigating PI-based combination regimens and novel investigational inhibitors and discusses the future perspective in the treatment of multiple myeloma. Keywords: multiple myeloma; proteasome inhibitors; bortezomib; carfilzomib; ixazomib 1. Introduction Multiple myeloma (MM) remains an incurable disease. Over the last ten years, the availability of new drugs, such as the proteasome inhibitors (PIs), the immunomodulatory drugs (IMiDs), the monoclonal antibodies (MoAbs), and the histone deacetylase inhibitors, have greatly advanced the treatment and improved the survival of patients with MM [1–3]. Proteasome inhibition has emerged as a crucial therapeutic strategy in the treatment of MM.
    [Show full text]
  • Efficacy and Safety Results from a Phase 1B/2, Multicenter, Open-Label
    Leukemia Research 83 (2019) 106172 Contents lists available at ScienceDirect Leukemia Research journal homepage: www.elsevier.com/locate/leukres Research paper Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or T refractory multiple myeloma ⁎ Parameswaran Haria, , Claudia E. Paba-Pradab, Peter M. Voorheesc, John Fryed, Yu-Lin Changd, Philippe Moreaue,Jeffrey Zonderf, Ralph Bocciag, Kenneth H. Shainh a Medical College of Wisconsin, Milwaukee, WI, USA b Dana-Farber Cancer Institute, Boston, MA, USA c Levine Cancer Institute, Atrium Health, Charlotte, NC, USA d Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA e University Hospital, Nantes, France f Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA g Center for Cancer and Blood Disorders, Bethesda, MD, USA h Moffitt Cancer Center, Tampa, FL, USA ARTICLE INFO ABSTRACT Keywords: Oprozomib is an oral proteasome inhibitor with activity in multiple myeloma (MM). Our phase 1b/2 study Oprozomib examined the safety and efficacy of oprozomib with dexamethasone in patients with relapsed and refractory MM. Oral proteasome inhibitor Oprozomib was administered with a 5/14 or 2/7 schedule with dexamethasone. Phase 1b primary objectives Dexamethasone were to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of oprozomib; Multiple myeloma phase 2 primary objectives were to determine overall response rate (ORR) and safety/tolerability of the RP2D. Maximum tolerated dose Between July 2, 2013, and August 29, 2016, data were available on 65 enrolled patients (5/14 schedule, n = 19; 2/7 schedule, n = 46).
    [Show full text]
  • US Managed Care Perspectives on Assessment and Uptake Of
    Vol. 18, No. 1, 2015 Educating Medical Directors of Employers, Health Plans and Provider Systems FEATURED ARTICLES INCLUDE: GBEMTI Perspectives: U.S. Managed Care Perspectives on Assessment and Uptake of Molecular Diagnostics: State of the Union and Areas for Additional Improvement Advanced Non-Small Cell Lung Cancer: Toward a Personalized Approach Risk Stratification: The Practical Implementation of a Powerful Tool THE NEW NONINVASIVE OPTION FOR AVERAGE- RISK PATIENTS WHO AVOID COLONOSCOPY Cologuard is the colorectal cancer screening test that uses innovative stool DNA technology to detect cancer with 92% sensitivity and 87% specificity.1 It’s noninvasive and easy to use, with no special preparation required. No wonder patients are excited—and you will be, too. Covered by Medicare. CologuardTest.com. Cologuard is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma (AA) and should be followed by diagnostic colonoscopy. Cologuard is indicated to screen adults of either sex, 50 years or older, who are at typical average-risk for CRC. Cologuard is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high risk individuals. Rx only. 1. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(4):1987-97. Cologuard is a registered trademark of Exact Sciences Corporation. ©2015 Exact Sciences Corporation. All rights reserved. CG-00120-01-January 2015 XXXXX_NAMCP_PrintAd_1-0.indd 1 1/22/15 4:14 PM Journal of Managed Care Medicine JMCM The Official Journal of the NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS MEDICAL DIRECTORS INSTITUTE JOURNAL OF MANAGED CARE A Peer-Reviewed Publication MEDICINE Vol.
    [Show full text]
  • Establishing a Preclinical Multidisciplinary Board for Brain Tumors Birgit V
    Published OnlineFirst January 4, 2018; DOI: 10.1158/1078-0432.CCR-17-2168 Cancer Therapy: Preclinical Clinical Cancer Research Establishing a Preclinical Multidisciplinary Board for Brain Tumors Birgit V. Nimmervoll1, Nidal Boulos2, Brandon Bianski3, Jason Dapper4, Michael DeCuypere5, Anang Shelat6, Sabrina Terranova1, Hope E. Terhune4, Amar Gajjar7, Yogesh T. Patel8, Burgess B. Freeman9, Arzu Onar-Thomas10, Clinton F. Stewart11, Martine F. Roussel12, R. Kipling Guy6,13, Thomas E. Merchant3, Christopher Calabrese14, Karen D. Wright15, and Richard J. Gilbertson1 Abstract Purpose: Curing all children with brain tumors will require an Results: Mouse models displayed distinct patterns of response understanding of how each subtype responds to conventional to surgery, irradiation, and chemotherapy that varied with tumor treatments and how best to combine existing and novel therapies. subtype. Repurposing screens identified 3-hour infusions of It is extremely challenging to acquire this knowledge in the clinic gemcitabine as a relatively nontoxic and efficacious treatment of alone, especially among patients with rare tumors. Therefore, we SEP and CPC. Combination neurosurgery, fractionated irradia- developed a preclinical brain tumor platform to test combina- tion, and gemcitabine proved significantly more effective than tions of conventional and novel therapies in a manner that closely surgery and irradiation alone, curing one half of all animals with recapitulates clinic trials. aggressive forms of SEP. Experimental Design: A multidisciplinary team was established Conclusions: We report a comprehensive preclinical trial to design and conduct neurosurgical, fractionated radiotherapy platform to assess the therapeutic activity of conventional and chemotherapy studies, alone or in combination, in accurate and novel treatments among rare brain tumor subtypes.
    [Show full text]
  • Figure S1. Effect of 4NQO, A-1155463 Or Their Combination on General Transcription, Translation, and Specific Apoptotic Proteins
    Supplementary figures and tables Figure S1. Effect of 4NQO, A-1155463 or their combination on general transcription, translation, and specific apoptotic proteins. (a) RPE cells were treated with 1 M 4NQO, 1 M A-1155463 or their combination. Control cells were treated with 0.1% DMSO. [alpha-P32]UTP was added to cell culture medium to label newly transcribed cellular RNA. Total RNA was isolated and subjected to agarose gel electrophoresis followed by radioautography. (b) RPE cells were treated as for (a). [35S] methionine and cysteine were added to methionine- and cysteine-free culture medium to label newly synthetized cellular proteins. Cells were lysed and proteins were separated on SDS-polyacrylamide gel. 35S-labelled proteins were detected using radioautography. (c) RPE cells were treated as for (a). Relative levels of apoptosis- related proteins were determined using proteome profiler human apoptosis kit (n=2). Figure S2. Chemical structures of monomeric MB2Py(Ac) and dimeric DB2Py(n) bisbenzimidazole-pyrroles, as well as dimeric bisbenzimidazoles DBA(n). Table S1. The active compounds of 48 commonly prescribed drugs in Norway, their suppliers and catalogue numbers. Purity, Drug CAS MW Formula Cat N % Supplier 17α- E4876- Ethynylestradiol 57-63-6 296 C20H24O2 100MG ≥98 Sigma Aldrich 4- Acetamidophenol 103-90-2 151 C8H9NO2 102330050 98 Acros Organics Acetylsalicylic acid 50-78-2 180 C9H8O4 AC158180500 99 Acros Organics Amlodipine 88150-42-9 409 C26H31ClN2O8S CAYM14838 ≥98 Cayman Chemicals 134523-03- Atorvastatin 8 559 C33H35FN2O5 CAYM10493
    [Show full text]
  • A Phase 1B/2 Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström
    Author Manuscript Published OnlineFirst on May 29, 2019; DOI: 10.1158/1078-0432.CCR-18-3728 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 A Phase 1b/2 Study of Oprozomib in Patients With Advanced Multiple Myeloma and Waldenström 2 Macroglobulinemia 3 4 Running title: Oprozomib in myeloma and macroglobulinemia 5 6 Irene M. Ghobrial,1 Ravi Vij,2 David Siegel,3 Ashraf Badros,4 Jonathan Kaufman,5 Noopur Raje,6 Andrzej 7 Jakubowiak,7 Michael R. Savona,8 Mihaela Obreja,9 and Jesus G. Berdeja10 8 9 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2Department of Medicine, 10 Washington University School of Medicine, St Louis, MO; 3Myeloma Division, John Theurer Cancer 11 Center at Hackensack University Medical Center, Hackensack, NJ; 4 Multiple Myeloma Service, University 12 of Maryland School of Medicine, Baltimore, MD; 5Department of Hematology and Medical Oncology, 13 Winship Cancer Institute of Emory University, Emory University, Atlanta, GA; 6Department of 14 Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, 15 MA; 7Myeloma Program, University of Chicago Medical Center, Chicago, IL; 8Department of Medicine, 16 Vanderbilt University School of Medicine, Nashville, TN; 9 Department of Biostatistics, Amgen Inc., 17 Thousand Oaks, CA; and 10Myeloma Research, Sarah Cannon Research Institute, Nashville, TN 18 Financial support: This study was supported by Amgen Inc. 19 20 Correspondence: Irene M. Ghobrial; Dana-Farber Cancer Institute; 450 Brookline Avenue, Boston, MA 21 02215; Phone: 617-632-4218; Email: [email protected] 22 Keywords: Oprozomib, multiple myeloma, Waldenström macroglobulinemia.
    [Show full text]
  • Oprozomib in Patients with Newly Diagnosed Multiple Myeloma Parameswaran Hari1, Jeffrey V
    Hari et al. Blood Cancer Journal (2019) 9:66 https://doi.org/10.1038/s41408-019-0232-6 Blood Cancer Journal CORRESPONDENCE Open Access Oprozomib in patients with newly diagnosed multiple myeloma Parameswaran Hari1, Jeffrey V. Matous2, Peter M. Voorhees3,KennethH.Shain4, Mihaela Obreja5,JohnFrye5, Hisaki Fujii5, Andrzej J. Jakubowiak6, Davide Rossi7 and Pieter Sonneveld8 Dear Editor, OPZ003 (NCT01881789) and OPZ006 (NCT02072863) Treatment options for newly diagnosed multiple mye- were multicenter, open-label, phase 1b/2 studies. Adult, loma (NDMM) commonly include triplet regimens using transplant-ineligible NDMM patients were eligible. The the first-in-class proteasome inhibitor (PI) bortezomib, a primary objective of the phase 1b portions was to deter- corticosteroid, and an alkylator or immunomodulator1,2. mine oprozomib’s maximum tolerated dose (MTD) using Patients ultimately relapse with these regimens, and a standard 3 + 3 dose escalation schema. Efficacy was a bortezomib is associated with peripheral neuropathy primary objective of the phase 2 portions. Disease (PN)3. Additional effective, well-tolerated, and convenient response was assessed by investigators according to frontline treatment options are needed. International Myeloma Working Group – Uniform Carfilzomib is an intravenously administered, second- Response Criteria. Duration of response (DOR) was generation, irreversible tetrapeptide PI approved for defined as time from achievement of a partial response relapsed or refractory multiple myeloma (RRMM)4.In (PR) or better to confirmed disease progression or death frontline studies, carfilzomib treatment resulted in hiqh- due to any cause. Progression-free survival (PFS) was – quality responses with low PN rates5 8, demonstrating defined as time from treatment initiation to disease pro- 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; therapeutic potential of second-generation, irreversible gression or death due to any cause.
    [Show full text]
  • WO 2017/187156 Al 02 November 2017 (02.11.2017) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/187156 Al 02 November 2017 (02.11.2017) W !P O PCT (51) International Patent Classification: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, A61K 38/04 (2006.01) A61P 35/00 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, A61K 38/12 (2006.01) A61K 38/06 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 31/365 {2006.01) A61K 45/06 {2006.01) KM, ML, MR, NE, SN, TD, TG). A61K 31/69 (2006.01) A61K 31/4015 (2006.01) C07D 303/36 (2006.01) Published: — with international search report (Art. 21(3)) (21) International Application Number: PCT/GB2017/05 1148 (22) International Filing Date: 25 April 2017 (25.04.2017) (25) Filing Language: English (26) Publication Langi English (30) Priority Data: 1607279.5 26 April 2016 (26.04.2016) GB (71) Applicant: BIG DNA LTD [GB/GB]; Wallace Building, Roslin Biocentre, Roslin, Midlothian EH25 9PP (GB). (72) Inventors: MARCH, John, Bernard; c/o Big DNA Ltd, Wallace Building, Roslin BioCentre, Roslin Midlothian EH25 9PP (GB). CLARK, Ewan, Mcintosh; c/o Big DNA Ltd, Wallace Building, Roslin BioCentre, Roslin Midlothi an EH25 9PP (GB). (74) Agent: HGF LIMITED (LEEDS); 1 City Walk, Leeds West Yorkshire LSI 1 9DX (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Waldenström Macroglobulinemia
    Waldenström Macroglobulinemia No. 20 in a series providing the latest information for patients, caregivers and healthcare professionals Introduction Highlights “Lymphoma” is the name for many different types of y Waldenström macroglobulinemia (WM) is a rare cancer that originate in lymphocytes (white blood cells). and slow-growing subtype of non-Hodgkin There are three types of lymphocytes: B lymphocytes lymphoma that affects white blood cells. (B cells), T lymphocytes (T cells) and natural killer (NK) cells. B lymphocytes make antibodies to fight infection; y A main characteristic of WM is the T lymphocytes have many functions, including helping overproduction of a monoclonal protein called B lymphocytes to make the antibodies that fight infection; “immunoglobulin M” (IgM). Immunoglobulin M and natural killer cells that attack cancer cells and viruses. can result in a thickening of the blood and may cause several other symptoms. Lymphocytes go through several stages of development. y Over 90 percent of WM patients have a They are created in the bone marrow and then move mutation in the MYD88 gene in their lymphoma through the blood to the lymphatic system. The final cells. The mutation turns on pathways that stage of B-lymphocyte development is a mature, sustain the growth and survival of WM cells. immunoglobulin-producing plasma cell. y Some patients with WM do not have symptoms Lymphoma may arise in any of these types of at diagnosis and may not require treatment lymphocytes but, in general, B-cell lymphomas are for years. In these cases, patients are closely more common than T-cell lymphomas. Lymphoma is monitored for symptoms in an approach known divided into two major categories: Hodgkin lymphoma as “watch and wait.” Active treatment is started (HL) and non-Hodgkin lymphoma (NHL).
    [Show full text]